Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
Merus
company
About
Merus is a biomedical company engaged in the discovery and development of antibody-based biopharmaceuticals.
- 101 - 250
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- €21.70M
- Industries
- Biotechnology,Health Care,Medical,Therapeutics
- Founded date
- Jan 1, 2003
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Merus B.V., a biomedical company, engages in the discovery and development of antibody-based biopharmaceuticals. It develops Oligoclonics technology that offers a class of human antibodies, called Oligoclonics. Oligoclonics is a concept whereby a mixture of various human therapeutic antibodies, directed to a common antigen are produced from a single cell clone. The company was founded in 2003 and is based in Driebergen, the Netherlands.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
€21.70M
Merus has raised a total of
€21.70M
in funding over 2 rounds. Their latest funding was raised on
Jan 29, 2010 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 29, 2010 | Series B | €21.70M | 1 |
Pfizer
|
— | Detail |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
